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Abstract
Background:  Growth hormone-releasing hormone (GHRH) plasmid-based therapy for the
treatment of chronic renal failure and its complications was examined. Companion dogs (13.1 ± 0.8
years, 29.4 ± 5.01 kg) and cats (13.2 ± 0.9 years, 8.5 ± 0.37 kg) received a single 0.4 mg or 0.1 mg
species-specific plasmid injection, respectively, intramuscularly followed by electroporation, and
analyzed up to 75 days post-treatment; controls underwent electroporation without plasmid
administration.
Results: Plasmid-treated animals showed an increase in body weight (dogs 22.5% and cats 3.2%)
compared to control animals, and displayed improved quality of life parameters including significant
increases in appetite, activity, mentation and exercise tolerance levels. Insulin-like growth factor I
(IGF-I, the downstream effector of GHRH) levels were increased in the plasmid treated animals.
Hematological parameters were also significantly improved. Protein metabolism changes were
observed suggesting a shift from a catabolic to an anabolic state in the treated animals. Blood urea
nitrogen and creatinine did not show any significant changes suggesting maintenance of kidney
function whereas the control animal's renal function deteriorated. Treated animals survived longer
than control animals with 70% of dogs and 80% of cats surviving until study day 75. Only 17% and
40% of the control dogs and cats, respectively, survived to day 75.
Conclusion:  Improved quality of life, survival and general well-being indicate that further
investigation is warranted, and show the potential of a plasmid-based therapy by electroporation
in preventing and managing complications of renal insufficiency.
Background
Renal failure and its complications, such as anemia and
decreased life expectancy, can be related to primary kid-
ney disease, such as glomerulonephritis or pyelonephritis,
or are a consequence of long-term chronic diseases such as
cancer, hypertension, heart failure, diabetes or severe
allergic reactions [1,2]. The predicted increase in the
number of people with renal failure and end-stage renal
disease places an enormous burden on the healthcare pro-
vider system [3]. Strategies are therefore needed to
improve the prevention, detection [4] and treatment of
kidney disease.
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Chronic renal failure (CRF) can affect the growth hor-
mone releasing hormone/growth hormone/insulin-like
growth factor-I (GHRH/GH/IGF-I) axis [5] which can lead
to growth retardation in children and is associated with
increased morbidity and mortality [6,7]. The action of GH
and its mediator, IGF-I, on body composition, protein,
glucose, and bone metabolism offers real therapeutic
options for these patients, including the improvement of
the catabolic state in adults with end-stage renal failure.
Recombinant human GH has been shown to be effective
in promoting growth in children of short stature with CRF
both prior to and following renal transplantation [8].
Wuhl and co-investigators showed that in a few pilot stud-
ies and two placebo-controlled studies of 6 months dura-
tion, GH treatment in adults on dialysis showed clear
anabolic effects resulting in a significant increase in lean
body mass [9]. However, existing treatments for condi-
tions associated with renal failure, such as anemia, wast-
ing, immune dysfunction, or other conditions have some
significant drawbacks: the daily injection routine is
impractical and often associated with local or systemic
adverse effects and may lead to non-compliance in
patients.
The technique of electroporation (EP) is an important
development for gene therapeutic approaches with the
potential to treat many conditions with a single low dose
of plasmid resulting in long-term effects. Previous studies
using GHRH showed that plasmid therapy with EP is scal-
able and represents a promising approach to induce pro-
duction and regulated secretion of proteins in both large
animal models and in humans [10-13]. Others have also
reported successful EP-mediated gene therapy or DNA
vaccination in large animals [14-16]. In this current open
label pilot study we have analyzed the impact of the plas-
mid GHRH/EP approach to treat renal failure and its com-
plications in affected companion animals (dogs and cats)
as a model for human disease. This approach has proved
successful in a Phase I veterinary trial where 9 dogs with
malignant melanoma were successfully treated with a
xenogeneic human tyrosinase DNA vaccination delivered
by the Biojector 2000 jet delivery device [17]. Further-
more, the use of companion animals provides an impor-
tant bridge between preclinical studies and clinical trials
while providing important information for both veteri-
narians and researchers involved in the study of human
disease and treatments. Our results show that this gene
therapeutic approach by EP can treat some of the compli-
cations of kidney failure, while increasing the well being,
quality of life and life expectancy of CRF animals.
Results
Sixty companion animals were enrolled in this pilot
GHRH-study (30 cats and 30 dogs); an additional 27 were
enrolled as control animals (15 cats and 12 dogs) (Table
1). No adverse effects of the plasmid administration were
noted by the owners or the veterinarians caring for the
animals. As this was a pilot study enlisting chronically ill
companion animals, data at all time points was not avail-
able or collected due to owner compliance, especially for
control animals, thus a statistical analysis was not per-
formed for some of the parameters measured. The
number of animals analyzed at each data point is speci-
fied in the cases where data from all animals was not avail-
able.
Treatment with GHRH led to an increase in survival. By
day 75, only 40% (n = 6 out of 15) of the control cats were
still alive whereas 80% (n = 24 out of 30) of the GHRH-
treated cats survived; only 17% (n = 2 out of 12) of the
control dogs survived until day 75 whereas 70% (n = 21
out of 30) of the GHRH-treated dogs survived.
Body weight increased for the GHRH-treated dogs. Body
weight in GHRH-treated cats remained stable with only a
slight increase (Table 2). For the GHRH-treated dogs, the
initial average body weight was 29.44 ± 5.01 kg (n = 27,
day 0) and increased to 36.08 ± 9.07 kg (P < 0.05) by day
40 (n = 21), an improvement of 22.5%. The GHRH-
treated cats body weight changed from 8.52 ± 0.37 kg at
day 0 (n = 27) to 8.80 ± 0.58 kg at day 40 (n = 27), an
improvement of 3.2%. However, the control animals
exhibited a reduction in body weight over the study
period. The body weight of the control cats decreased
from an initial average of 10.44 ± 1.48 kg (n = 6) to 7.05
± 0.23 kg and the control dogs weight decreased from an
initial average of 15.95 ± 4.84 kg (n = 4) to 11.09 ± 3.05
kg at day 20. These control results were not statistically
significant most likely due to the small number of com-
panion animals that were able to be analyzed.
Quality of life (QOL) parameters were not individually
tabulated for control animals, but overall the attending
veterinarians noted stable to worsening performance.
Assessment of QOL parameters as determined by the
owner's for treated dogs and cats was collected from base-
line to day 60 post-treatment, and is shown in Tables 3
and 4 respectively. The overall QOL significantly
improved for treated dogs compared to baseline. In partic-
ular, for treated dogs activity and exercise levels signifi-
cantly improved, and appetite and mentation improved.
For treated cats, the overall QOL significantly improved
throughout the duration of the study, in particular, activ-
ity, exercise, mentation and appetite. Importantly, these
findings regarding the QOL are similar to previously pub-
lished results for dogs with spontaneous malignancies
that were treated with a GHRH-expressing plasmid [13].
Cats and dogs with CRF treated with plasmid-GHRH
showed an increase in their IGF-I levels compared to their
baseline. Significantly increased IGF-I levels throughoutBMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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Table 1: Dog and cat breeds and age at enrollment.
Treated Breed Dog Age at enrollment 
(yrs)
Weight at 
enrollment (lbs)
Breed Cat Age at enrollment 
(yrs)
Weight at 
enrollment (lbs)
T1 Poodle 10.9 9.5 DSH 13.9 8.5
T2 Shih Tzu 6.2 6.62 Calico 17.8 9.75
T3 Airedale 8.9 65 DMH 15.0 6
T4 Terrier Mix 18.0 11.31 DMH 15.1 13.41
T5 Bulldog 1.6 66 Bengal 9.8 9.75
T6 Greyhound 11.9 62 DSH 13.1 7.5
T7 Poodle 15.7 6.25 DSH 17.9 6
T8 Mixed 17.1 18.4 DSH 1.0 9
T9 Labrador 17.2 48.2 DSH 17.1 6
T10 Labrador 9.7 65.7 DLH 14.1 7.69
T11 Greyhound 19.1 51.3 DSH 19.1 10.53
T12 West Highland 
Terrier
15.1 22 Persian 17.1 7.1
T13 Yorkshire Terrier 13.7 10.8 DLH 6.4 10.5
T14 Yorkshire Terrier 11.4 3.31 DSH 17.1 7.4
T15 Bichon Frise 16.3 8.13 DSH 17.1 8.06
T16 Australian Shepherd 15.2 29.06 Persian 19.1 5.88
T17 Pomeranian 13.0 4.19 DLH 3.1 10.25
T18 Shih Tzu 10.3 16.56 Siamese 2.1 9.75
T19 Labrador 9.1 78.6 Himalayan 6.1 8
T20 Chihuahua 16.6 4.31 DSH 12.1 7
T21 Rat Terrier 15.9 10 DSH 14.9 6
T22 Cocker Spaniel 10.8 27.4 DSH 15.9 7.13
T23 Pomeranian 12.8 4.8 Siamese 14.1 9.19
T24 Terrier Mix 15.2 29.9 Siamese 16.9 12
T25 Terrier Mix 13.8 13.5 DSH 13.2 11.31
T26 Terrier Mix 19.3 17.75 DLH 14.5 8.31
T27 German Shepherd 6.9 68.4 DSH 11.2 6.4
T28 Shih Tzu 15.3 16 Maine Coon 15.2 7.12
T29 Dachshund Mix 16.9 7.3 DSH 11.2 8.88
T30 Labrador 10.0 101 DSH 14.2 11.25
Average 13.1 ± 0.8 29.44 ± 5.01 13.2 ± 0.9 8.52 ± 0.37
Control Breed Dog Age at enrollment 
(yrs)
Weight at 
enrollment (lbs)
Breed Cat Age at enrollment 
(yrs)
Weight at 
enrollment (lbs)
C1 Labrador 13.92 DSH 10.87
C2 Welsh Corgi 10.15 28.6 DSH 7.04
C3 Maltese 11.16 5 DSH 15.76 9.3
C4 Shih Tzu 10.00 15.2 DSH 13.68 9.94
C5 Poodle 13.75 DSH 7.33 7.56
C6 Yorkshire/Poodle 14.54 Siamese 14.44 11.69
C7 Lhasa apso 15.84 15 DLH 18.59 7.12
C8 Chihuahua/Terrier 13.50 DLH 12.36 17
C9 Dalmatian 10.66 Birman 11.42
C10 Lhasa apso 12.72 DLH 16.88
C11 Brussels Griffon 12.79 DSH 15.82
C12 Am Eskimo 15.81 DSH 14.85
C13 Persian 10.31
C14 DSH 16.02
C15 DSH 14.57
Average 12.9 ± 0.59 15.95 ± 4.84 13.33 ± 0.87 10.44 ± 1.48BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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the study period were seen in 72% of dogs and 65% of cats
(P < 0.05) when compared to day 0 (Figure 1).
In GHRH injected cats and dogs, improvements in hema-
tological parameters compared to controls were obtained
as early as twenty days after the plasmid injection. Tables
5 and 6 show hematocrit (PCV), hemoglobin (Hb), red
blood cell count (RBC), and mean red cell hemoglobin
(MHC) in dogs and cats with CRF treated with plasmid-
mediated GHRH therapy, as well as control animals.
Some disparities in response were observed between cats
and dogs. This was most probably due to the heterogene-
ous nature of the groups, the relative moderate number of
animals enrolled in the study and species differences. Per-
centage differences are indicated, with treated dogs show-
ing significant changes up to 10.9% when compared to
baseline levels that were below normal ranges. Hemato-
logical parameters for control dogs were stable through-
out the study although a slight decrease was noted.
Overall, the hematological parameters improved for the
GHRH-treated animals, while remaining within or just
below normal levels. Control animals displayed better
hematological parameters at the time of enrollment com-
pared to GHRH-treated animals. Increased circulating lev-
els of iron were seen in the GHRH-treated dogs compared
to baseline (Figure 2, P < 0.05). No significant changes in
circulating levels of iron were observed in the GHRH-
treated cats.
Serum albumin and total protein values in cats and dogs
with CRF were also measured. The analysis of serum albu-
min (normal range for cats 2.4–3.5 g/dl) for the GHRH-
treated cats showed a 13% increase at 20 days post-treat-
ment (P < 0.001). In addition, total protein (normal range
for cats 5.3–8.5 g/dl) in GHRH-treated cats increased 9%
(P < 0.001). These changes correlated with an improved
protein metabolism, consistent with a change from a cat-
abolic state to an anabolic state. Control cats did not sig-
nificantly differ from day 0 (Figure 3). Minor increases
were observed in the GHRH-treated dogs although these
findings were not significant.
Blood urea nitrogen (BUN) and creatinine values (indica-
tors of renal function) were examined in dogs and cats
with CRF treated with plasmid-mediated GHRH therapy.
Analysis of BUN levels for the GHRH-treated dogs showed
a 17% reduction, and in concert a 16% decrease in creati-
nine levels, whereas in control dogs BUN and creatinine
levels increased by day 75 compared to day 0 (Figure 4A
&4B). BUN/creatinine ratios in control cats increased
from 18.15 ± 1.58 (day 0) to 20.46 ± 2.26 (day 75, P <
0.17), whereas the BUN/creatinine ratios in the GHRH-
treated cats remained stable (Figure 4C). Overall kidney
function was maintained in GHRH-treated dogs and cats
whereas the controls demonstrated a trend towards dete-
rioration of kidney function. All other parameters meas-
ured did not change significantly.
Discussion
At present there are approximately 30 million American's
affected by chronic kidney disease, with an estimated 2.2
million requiring treatment for end-stage renal disease by
2030, greatly impacting the healthcare system [18]. Mal-
nutrition and wasting are important determinants of mor-
bidity and mortality in patients with CRF on dialysis. Even
patients with a relatively modest degree of chronic renal
insufficiency are characterized by reduced lean body mass,
bone mineral content, and basal energy expenditure [19].
In humans CRF has been linked to a high prevalence of
anemia in an elderly population (64.9% with vs. 55.7%
without CRF) with the greater risk of anemia in the pres-
ence of CRF increasing with age [20]. Most cases of CRF
are associated with aging and it is one of the most com-
mon illnesses of geriatric cats and dogs [21]. Approxi-
mately one in five cats over the age of 15 yrs has CRF and
it is estimated to occur 3 times more frequent in cats than
dogs.
Table 2: Treated dog and cat average body weights during the study.
Treated dogs
Day 1 Day 20 Day 40 Day 60
Average weight (lbs) ± SEM 29.44 ± 5.01 25.25 ± 4.99 36.08 ± 9.07 33.14 ± 12.01
n 30 22 10 6
Ttest, P value 0.046 0.166
% Change from day 1 22.54 12.55
Treated cats
Day 1 Day 20 Day 40 Day 60
Average weight (lbs) ± SEM 8.52 ± 0.37 8.78 ± 0.44 8.80 ± 0.58 8.69 ± 0.49
n 30 22 14 10
Ttest, P value 0.456 0.221 0.198
% Change from day 1 2.97 3.24 1.99BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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As CRF has limited therapeutic options for both humans
and pets any adjuvant therapy that delays associated dis-
orders in these patients is of high interest. Unfortunately,
the lack of efficient drug therapy for supporting CRF
patients significantly increases their morbidity and mor-
tality [22]. Currently, chronic dialysis or kidney transplant
are the most common forms of treatment for humans. For
pets, most studies focus on nutrition and dietary changes
as the only available existing therapy [23]. It has been pre-
viously shown that the administration of a GHRH-analog
had also an immune-enhancing effect on healthy aging
individuals through stimulation of the GHRH/GH/IGF-I
axis [24]. Administration of GHRH to CRF patients may
improve their quality of life by acting as an immune-
enhancing agent and treating their anemia. Here we show
that a one-time treatment with a plasmid expressing
GHRH followed by EP can improve the outcome of com-
panion animals with renal insufficiency.
In this open label study we have enrolled companion ani-
mals for testing of a plasmid-mediated GHRH gene ther-
apy in a heterogeneous animal population that is more
Table 3: Quality of life assessment for GHRH-treated dogs.
Assessment Day 0 Day 20 Day 40 Day 60
Overall QOL Average score
n
% change
P-value vs. Day 0
3.08 ± 0.05
n = 26
3.43 ± 0.18*
n = 23
11.63%
0.06
3.39 ± 0.20
n = 18
10.14%
0.10
3.71 ± 0.17
n = 17
20.44%
0.0005
Body Weight Average score
n
% change
P-value vs. Day 0
3.0 ± 0.0
n = 28
3.0 ± 0.11
n = 19
0.0%
0.5
3.13 ± 0.20
n = 16
4.17%
0.27
3.18 ± 0.15
n = 17
5.88%
0.14
Activity Level Average score
n
% change
P-value vs. Day 0
2.97 ± 0.08
n = 29
3.52 ± 0.19
n = 23
18.76%
0.02
3.32 ± 0.19
n = 22
11.89%
0.03
3.67 ± 0.14
n = 18
23.64%
0.0001
Exercise Tolerance Average score
n
% change
P-value vs. Day 0
3.07 ± 0.07
n = 29
3.21 ± 0.14
n = 23
4.84%
0.19
3.32 ± 0.19
n = 22
8.12%
0.10
3.72 ± 0.16
n = 18
21.29%
0.0003
Mentation Average score
n
% change
P-value vs. Day 0
3.14 ± 0.08
n = 29
3.43 ± 0.15
n = 23
9.46%
0.10
3.14 ± 0.20
n = 21
0.16%
0.5
3.47 ± 0.18
n = 17
10.60%
0.052
Appetite Average score
n
% change
P-value vs. Day 0
2.98 ± 0.07
n = 29
3.48 ± 0.19
n = 23
16.61%
0.01
3.19 ± 0.21
n = 21
6.96%
0.24
3.24 ± 0.18
n = 17
8.47%
0.07
Thirst Average score
n
% change
P-value vs. Day 0
3.0 ± 0.0
n = 29
3.13 ± 0.14
n = 23
4.35
0.19
3.05 ± 0.15
n = 21
1.56%
0.37
3.0 ± 0.08
n = 18
0%
0.5
Urination Frequency Average score
n
% change
P-value vs. Day 0
3.0 ± 0.0
n = 29
3.04 ± 0.13
n = 23
1.45%
0.37
2.95 ± 0.11
n = 21
-1.59%
0.33
3.11 ± 0.08
n = 18
3.70%
0.08
Bowel Movement Frequency Average score
n
% change
P-value vs. Day 0
3.04 ± 0.04
n = 28
3.09 ± 0.15
n = 23
1.69%
0.29
3.0 ± 0.12
n = 21
-1.18%
0.5
3.0 ± 0.0
n = 18
-1.18%
NS
Diarrhea Frequency Average score
n
% change
P-value vs. Day 0
3.10 ± 0.06
n = 29
3.0 ± 0.0
n = 23
-3.33%
NS
3.05 ± 0.05
n = 21
-1.80%
0.16
3.0 ± 0.0
n = 18
-3.33%
0.17
Vomiting Frequency Average score
n
% change
P-value vs. Day 0
3.07 ± 0.05
n = 29
2.96 ± 0.04
n = 23
-3.66%
0.04
3.05 ± 0.05
n = 21
-0.70%
0.29
3.03 ± 0.03
n = 18
-1.34%
0.09
Abbreviations: NS, not significant Quality of life parameters from day 0 to day 60 of study where 1 = significantly decreased, 2 = decreased, 3 = no 
change, 4 = increased and 5 = significantly increased. For each parameter, data are presented as average ± SEM. Percentage changes over baseline 
values, as well as P value versus baseline values is included for each parameter at each time point.BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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representative of a human heterogeneous population
than small laboratory animals. Not only does the use of
companion animals provide important relevant informa-
tion for the design and follow-up of future clinical studies,
but will also allow the faster development of therapies for
veterinary use. It is known that GHRH stimulates the GH
and further the IGF-I axis during a catabolic state, which
in turn stimulates erythropoiesis [25]. IGF-I counteracts
apoptosis similarly to erythropoietin, and fosters prolifer-
ation of burst- and colony-forming units-erythroid [26].
Erythropoietic agents improve survival of CRF patients,
and here we have shown that a similar benefit should
apply for strategies that increase synthesis and bioavaila-
bility of IGF-I. Nevertheless, it is known that erythrocytes
of patients suffering from CRF are exposed to an increased
activity of free radicals, which leads to a decrease of eryth-
rocytes' stability and a lower resistance to hemolysis. The
intensity of changes is often according to the stage of the
disease and the efficiency of treatment. It is possible that
while the GHRH-treatment improves hematological
parameters and stabilizes renal function, these changes
are not sufficiently maintained long-term. This short-term
correction phenomenon has been previously observed in
both cats and dogs with CRF on erytopoietin treatment
Table 4: Quality of life assessment for GHRH-treated cats.
Assessment Day 0 Day 20 Day 40 Day 60
Overall QOL Average score
n
% change
P-value vs. Day 0
3.0 ± 0.05
n = 28
3.36 ± 0.11
n = 25
12.0%
0.008
3.43 ± 0.14
n = 22
14.39
0.001
3.68 ± 0.19
n = 19
22.81%
0.0009
Body Weight Average score
n
% change
P-value vs. Day 0
3.0 ± 0.0
n = 28
3.0 ± 0.11
n = 18
0.0%
0.5
3.36 ± 0.17
n = 14
11.9%
0.03
3.18 ± 0.21
n = 17
5.88%
0.21
Activity Level Average score
n
% change
P-value vs. Day 0
3.07 ± 0.10
n = 28
3.27 ± 0.13
n = 26
6.44%
0.13
3.66 ± 0.16
n = 22
19.13%
0.002
3.68 ± 0.19
n = 19
19.95%
0.005
Exercise Tolerance Average score
n
% change
P-value vs. Day 0
3.0 ± 0.05
n = 28
3.23 ± 0.08
n = 26
7.69%
0.02
3.26 ± 0.16
n = 21
8.73%
0.06
3.61 ± 0.18
n = 18
20.37%
0.002
Mentation Average score
n
% change
P-value vs. Day 0
3.0 ± 0.09
n = 28
3.46 ± 0.10
n = 26
15.38%
0.002
3.38 ± 0.15
n = 21
12.7%
0.008
3.45 ± 0.14
n = 19
14.91%
0.005
Appetite Average score
n
% change
P-value vs. Day 0
3.07 ± 0.11
n = 28
3.15 ± 0.16
n = 26
2.68%
0.26
3.23 ± 0.16
n = 22
5.07%
0.10
3.26 ± 0.13
n = 19
6.24%
0.04
Thirst Average score
n
% change
P-value vs. Day 0
3.07 ± 0.07
n = 28
3.12 ± 0.08
n = 26
1.43%
0.36
3.19 ± 0.13
n = 21
3.88%
0.27
3.0 ± 0.08
n = 19
-2.33%
0.36
Urination Frequency Average score
n
% change
P-value vs. Day 0
3.04 ± 0.06
n = 28
3.08 ± 0.08
n = 26
1.36%
0.36
3.05 ± 0.05
n = 22
0.32%
0.5
3.0 ± 0.0
n = 19
-1.17%
0.29
Bowel Movement Frequency Average score
n
% change
P-value vs. Day 0
2.93 ± 0.05
n = 28
2.92 ± 0.09
n = 26
-0.19%
0.5
3.0 ± 0.0
n = 22
2.44%
0.08
3.0 ± 0.0
n = 19
2.44%
0.08
Diarrhea Frequency Average score
n
% change
P-value vs. Day 0
3.0 ± 0.0
n = 28
3.04 ± 0.07
n = 26
1.28%
0.29
3.0 ± 0.0
n = 22
0.0%
NS
3.0 ± 0.0
n = 19
0.0%
NS
Vomiting Frequency Average score
n
% change
P-value vs. Day 0
3.07 ± 0.05
n = 28
3.04 ± 0.07
n = 26
-1.07%
0.33
3.0 ± 0.0
n = 22
-2.33%
0.08
3.05 ± 0.05
n = 19
-0.61%
0.29
Abbreviations: NS, not significant Quality of life parameters from day 0 to day 60 of study where 1 = significantly decreased, 2 = decreased, 3 = no 
change, 4 = increased and 5 = significantly increased. For each parameter, data are presented as average ± SEM. Percentage changes over baseline 
values, as well as P value versus baseline values is included for each parameter at each time point.BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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[27,28]. A follow up study will look at the possibility of
plasmid re-administration, and long-term effects of the
therapy. In this study, we also found that circulating iron
levels were increased in the treated patients, supporting
the hypothesis that the treatment may increase iron
absorption; this hypothesis will be tested in future studies.
Iron deficiency is often seen in CRF and is a common
cause of anemia [29]; therefore treatment with GHRH
may increase iron levels without the adverse effects of
parenteral iron therapy [30]. Our previous studies sup-
ported the hypothesis that an increase in GHRH will pos-
itively impact renal function, anemia, and immune
dysfunction, as well as reverse wasting, and extend life
expectancy of chronically ill patients. Currently, GHRH,
GH or IGF-I or their functional biological equivalents are
used as recombinant proteins in the treatment or manage-
ment of renal failure and impaired growth that is associ-
ated with this condition. Nonetheless, the necessity for
daily injections of GH [31] or other recombinant proteins
is a limiting factor as the patient's (or patient's owner's)
compliance is typically low and can result in sub-optimal
treatment outcomes.
The technique of EP is a significant development for the
field of gene therapy, given the ability to administer small
amounts of plasmid in a single dose with significant effect
[32,33]. Previous studies have shown that injection alone
of plasmid DNA results in relatively low uptake and
expression levels in comparison to injection in conjunc-
tion with EP [34], which can increase expression by up to
100 fold [35]. The use of EP along with optimization of
plasmid DNA for gene delivery or DNA vaccines has
become more popular as the parameters for successful
delivery without tissue damage have been elucidated [36],
while expression and immunogeneicity increased by 100-
to 1000 fold [37].
In larger animals, we have previously shown that GHRH
treatment followed by EP can dramatically improve the
conditions for companion animals with cancer, resulting
in an extended life span with a greatly improved quality of
life [13]. Hematological parameters were also signifi-
cantly improved in the GHRH-treated dogs, reversing the
cancer-associated anemia. Further studies have also
shown the effectiveness of GHRH treatment in combina-
tion with EP. Treatment of horses with laminitis, an
arthritic-like condition, reduced inflammation, and
increased survival [12]. We have previously discussed [11]
and experimentally shown [38] that it is not the injection
and/or the EP that determines these responses, but the
effects of GHRH expression after plasmid administration.
The similarity of the response across species (rats, pigs,
dogs and dairy cattle) suggests that the physiologic stimu-
lation of the GHRH axis is a fundamental component of
developmental physiology. Currently, DNA vaccines or
therapeutic plasmids and EP are being tested in humans
in a number of Phase I or I/II clinical trials (reviewed in
[39-41]).
In animal models, EP has been shown to increase the effi-
ciency of erythropoietin (Epo) gene transfer for the treat-
ment of CRF-associated anemia [42]. In mice and rats,
treatment of severe anemia associated with CRF with Epo-
gene electrotransfer, where hematocrit levels were similar
to those in humans with end-stage renal disease, resulted
in increased Epo and hematocrit levels [43,44]. EP also
increased the transduction of optimized Epo genes reduc-
ing inter-individual and species variability [45]. We are
aware of studies that have intramuscularly delivered an
Epo cDNA via recombinant adeno-associated virus in
monkeys and cats leading to responses against endog-
enous Epo [46]; nevertheless, this seems to not be the case
for GHRH. We have extensively used species-specific
GHRH plasmids in many models including large animals,
such as pigs. In one study, we attempted to measured anti-
GHRH antibodies, and no antibodies were detected
IGF-I levels in cats and dogs with chronic renal failure treated  with plasmid-mediated GHRH therapy Figure 1
IGF-I levels in cats and dogs with chronic renal failure 
treated with plasmid-mediated GHRH therapy. The 
results are presented as means ± SEM. (A). 75% of GHRH-
treated cats have increased IGF-I levels at 20–75 days after 
GHRH treatment (* P < 0.05). (B). 75% of GHRH-treated 
dogs have increased IGF-I levels at 20–75 days after GHRH 
treatment (* P < 0.05).
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against the species-specific muscle-produced GHRH [47].
Although Epo treatment is an important therapeutic strat-
egy for renal patients with anemia, the ability to treat
more than one of CRF's related complications with a sin-
gle therapeutic option is of great interest. The results of
this study indicated that EP of plasmid GHRH may be
such a solution, and an efficient and effective way to
impact many of the complications in chronically ill
patients.
Conclusion
As little as 0.1–0.4 mg of the GHRH therapeutic plasmid
(equivalent to 11–13 μg/kg) delivered under the proper
EP conditions in a single injection has an important bio-
logical impact by physiologically increasing IGF-I levels,
that stabilizes or improves kidney function and anemia,
has the ability to reverse wasting, and extend life in ailing
feline or canine subjects. The treated pets display
increased activity and appetite, with an increase in body
weight and overall improved health and survival rate.
Health-related quality of life is increasingly recognized as
an important outcome in clinical research and patient
care. Significant impairment in health-related quality of
life is seen with renal insufficiency, due to anemia, wast-
ing, and other complications of chronic disease or aging.
Results from these studies suggest that a clinical interven-
tion such as EP of plasmid GHRH could preserve renal
function and possibly improve the negative impact of kid-
ney disease on health-related quality of life.
Methods
Animals
All experiments were carried out according to NIH regula-
tions and the National Research Councils Guide for the
Care and Use of Animals, and with the specific approval
of the veterinarian clinics and the attending veterinarian
for each companion animal. To qualify for this study, all
companion animals must have had a confirmed diagnosis
of CRF from a licensed veterinarian, met eligibility
requirements, and have had the owner's written consent.
Patients from 11 different veterinary practices in the Hou-
ston, TX area participated in this studies. Diagnosis of
renal insufficiency by the animal's veterinarian was based
on physical examination, and biochemical and urinalysis
parameters (underlying conditions, including possible
causes of CRF, were not determined or recorded by the
attending veterinarian in a majority of cases). Prior to the
plasmid treatment, animals were treated with fluids (e.g.
Table 5: Hematological parameters in plasmid-GHRH treated dogs with CRF.
Assessment Red Blood
Cells
Hematocrit Hemoglobin Mean Red Cell Hemoglobin
Control Day 0 Average score
n
6.29 ± 0.5
n = 9
39.98 ± 2.6
n = 12
13.73 ± 1.0
n = 12
23.13 ± 0.8
n = 10
Day 20 Average score
% change
P-value vs. Day 0
6.43 ± 0.5
2.2%
P < 0.4
n = 6
39.42 ± 1.4
-1.4%
P < 0.2
n = 9
13.89 ± 0.8
1.1%
P < 0.2
n = 7
22.62 ± 0.7
-2.2%
P < 0.05
n = 6
Day 40 Average score
% change
P-value vs. Day 0
5.53 ± 0.4
-12%
P < 0.3
n = 6
37.82 ± 2.2
-5.4%
P < 0.3
n = 6
12.8 ± 1.0
-7.0%
P < 0.4
n = 6
23.08 ± 1.1
-0.2%
P < 0.26
n = 6
Day 60–75 Average score
% change
P-value vs. Day 0
5.69 ± 0.2
-10.0%
P < 0.5
n = 2
39.75 ± 1.2
-0.6%
P < 0.5
n = 2
12.1 ± 2.2
-12.0%
P < 0.5
n = 2
21.1 ± 3.1
-8.8%
P < 0.19
n = 2
Treated Day 0 Average score
n
4.84 ± 0.3
n = 30
34.95 ± 1.9
n = 30
11.48 ± 0.6
n = 30
23.88 ± 0.2
n = 30
Day 20 Average score
% change
P-value vs. Day 0
5.26 ± 0.3
8.6%
P < 0.02
n = 27
37.4 ± 1.8
7.0%
P < 0.1
n = 27
12.74 ± 0.6
10.9%
P < 0.01
n = 27
24.39 ± 0.3
2.1%
P < 0.02
n = 27
Day 40 Average score
% change
P-value vs. Day 0
5.13 ± 0.3
5.9%
P < 0.09
n = 26
36.73 ± 2.1
5.1%
P < 0.21
n = 26
12.53 ± 0.6
9.1%
P < 0.01
n = 26
24.58 ± 0.3
2.9%
P < 0.001
n = 26
Day 60–75 Average score
% change
P-value vs. Day 0
5.19 ± 0.3
7.1%
P < 0.15
n = 20
37.07 ± 2.2
6%
P < 0.25
n = 20
12.69 ± 0.8
9.1%
P < 0.02
n = 20
24.31 ± 0.4
1.8%
P < 0.1
n = 19
Hematological parameters are significantly improved with plasmid treatment compared to day 0. For dogs normal RBC 5.5–8.5 × 106/mm3; normal 
Ht 37–55%; and normal Hb 12–18 g/dl.BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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lactated Ringer's solution, saline, Normasol) or by special-
ized diet. If fitting the inclusion criteria, owners were
offered to have their pets receive the GHRH-treatment or
serve as controls in the study. Controls were maintained
on the standard of care therapy (fluids and diet) through-
out the study period. All animals were enrolled within a 6
months period (November to May). Dogs were treated
with a dog-specific GHRH-expressing plasmid on average
288.86 ± 90.34 days after initial diagnosis of CRF, while
cats were treated with a cat-specific GHRH-expressing
plasmid 255.60 ± 61.26 days after diagnosis. The condi-
tion of inclusion in our study was an estimated survival of
at least 20 days post-treatment (in order to allow for plas-
mid activation and expression of GHRH from the skeletal
muscle) when a second blood draw could be made. The
animals were weighed and bled before treatment and at
days 20, 40, and 75 post-injection. At each time point,
complete CBC and metabolic profiles were assessed by the
same independent laboratory (Antech Diagnostics, Irvine,
CA). Wellness forms were requested to be completed by
owners at each visit. Body weight, activity level, exercise
tolerance, mentation (attitude, alertness), appetite, thirst,
frequency of urination, number of bowel movements, fre-
quency of diarrhea, frequency of vomiting, and overall
quality of life were assessed with ratings of their pets con-
dition as significantly increased (5), increased (4), no
change (3), decreased (2) or significantly decreased (1).
Case-matched control dogs (12.90 ± 0.59 years, 25.49 ±
9.04 kg) and cats (13.33 ± 0.87 years, 10.44 ± 1.48 kg)
(those who's owners were offered, but did not wish to
have their pets treated with the GHRH-expressing plasmid
+ EP, and thus not receiving plasmid but standard renal
failure treatment, such as subcutaneous fluids when nec-
essary and specialized diet) identified suitable for inclu-
sion into the study by the attending veterinarian, were
evaluated for parameters that enter into the standard of
care; due to the deteriorating general state of control ani-
mals, the number of blood draws and quantity of blood
per draw was maintained to a minimum in these animals
in agreement with standard veterinary practice (i.e. hema-
tology and biochemistry parameters were evaluated, while
hormonal or other supplementary assays, such as iron or
IGF-I concentrations were not performed on these group).
For these parameters, baseline values were used for com-
parison in the GHRH-treated group.
Table 6: Hematological parameters in plasmid-GHRH treated cats with CRF.
Assessment Red Blood
Cells
Hematocrit Hemoglobin Mean Red Cell Hemoglobin
Control Day 0 Average score
n
7.19 ± .4
n = 12
31.68 ± 1.5
n = 13
11.02 ± .5
n = 12
15.44 ± .4
n = 12
Day 20 Average score
% change
P-value vs. Day 0
7.72 ± .5
7.3%
P < 0.16
n = 7
32.87 ± 2.0
3.8%
P < 0.30
n = 10
10.75 ± .8
-2.0%
P < 0.35
n = 8
14.27 ± .6
-8.0%
P < 0.06
n = 7
Day 40 Average score
% change
P-value vs. Day 0
7.36 ± .6
2.3%
P < 0.41
n = 8
32.17 ± 2.0
1.6%
P < 0.38
n = 10
10.27 ± .9
-7.0%
P < 0.05
n = 9
13.81 ± .7
-11.0%
P < 0.03
n = 8
Day 60–75 Average score
% change
P-value vs. Day 0
7.40 ± .3
2.9%
P < 0.47
n = 7
32.10 ± 1.1
1.3%
P < 0.32
n = 7
10.99 ± .5
-0.0%
P < 0.25
n = 7
14.9 ± .6
-4.0%
P < 0.08
n = 7
Treated Day 0 Average score
n
6.16 ± 0.3
n = 30
27.59 ± 1.1
n = 30
9.65 ± 0.7
n = 30
14.73 ± 0.2
n = 30
Day 20 Average score
% change
P-value vs. Day 0
6.71 ± 0.3
9.0%
P < 0.001
n = 29
30.46 ± 1.1
10.4%
P < 0.0009
n = 29
10.11 ± 0.4
4.7%
P < 0.22
n = 29
15.22 ± 0.3
3.3%
P < 0.003
n = 29
Day 40 Average score
% change
P-value vs. Day 0
6.35 ± 0.3
3.2%
P < 0.06
n = 26
28.23 ± 1.1
2.3%
P < 0.16
n = 26
9.65 ± 0.3
-0.07%
P < 0.47
n = 26
15.32 ± 0.3
4.0%
P < 0.001
n = 26
Day 60–75 Average score
% change
P-value vs. Day 0
6.42 ± 0.4
4.3%
P < 0.02
n = 19
29.18 ± 1.3
5.7%
P < 0.03
n = 20
9.82 ± 0.5
1.6%
P < 0.002
n = 19
15.46 ± 0.4
4.9%
P < 0.004
n = 19
Hematological parameters are significantly improved with plasmid treatment compared to day 0. For cats normal RBC 5.7–10.5 × 106/mm3; normal 
Ht 38–52%; and normal Hb 9–16 g/dl.BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
Page 10 of 13
(page number not for citation purposes)
Kidney Failure Dogs
Thirty dogs with kidney failure were used in this GHRH
study (Table 1) with twelve additional dogs for controls.
Creatinine levels had to be at least 2.5 mg/dl (normal
range: 0.4–1.8 mg/dl) and blood urea nitrogen at least 35
mg/dl (normal range: 7–27 mg/dl) for the animal to be
enrolled in the study. The average age of the dogs was 13.1
± 0.56 years. The dogs were injected with 0.4 mg of a dog
specific GHRH expressing plasmid, pSP-dog-GHRH.
Kidney Failure Cats
Thirty cats with kidney failure were used in GHRH studies
(Table 1) with fifteen additional cats as controls. Creati-
nine levels had to be at least 3.5 mg/dl (normal range:
0.8–2.3 mg/dl) and blood urea nitrogen had to be at least
45 mg/dl (normal range: 13.4–32.5 mg/dl) for the animal
to be enrolled in the study. The average age of the cats was
13.2 ± 0.66 years. The cats were injected with 0.1 mg of a
cat-specific expressing plasmid pSP-cat-GHRH.
DNA Constructs
The plasmid pSPc5-12-GHRH contains a 360-bp SPc5-12
synthetic promoter [48]. The cat and dog-GHRH cDNA
was cloned in our laboratory [49]; the transgene was syn-
thetically produced and sub-cloned into a synthetic plas-
mid previously described [49]. The dog-specific GHRH
expressing plasmid and cat-specific GHRH expressing
plasmid, for dogs and cats, respectively, were used in these
studies. Plasmids were prepared by batch fermentation
followed by membrane chromatography purification. The
endotoxin concentration was measured with Limulus
Amebocyte Lysate (LAL) kinetic chromogenic assay, and
the A405 of samples were recorded with SpectraMAX
PLUS 384 Microplate Reader after a period of one hour
incubation at 37°C. The endotoxin levels for both prepa-
rations were less than 2 EU/mg of plasmid.
Intramuscular injection with electroporation of plasmid 
DNA in canine or feline subjects with kidney failure
Endotoxin-free plasmid preparation of species-specific
pSP-GHRH was diluted in sterile water for injection to 2
mg/mL, and low molecular weight poly-L-glutamate
(LGS) sodium salt solution was added to 1% w/w. Dogs
and cats in this study were anesthetized with isofluorane
(5% for induction, 2% for maintenance). While anesthe-
tized, plasmid was injected directly into the semitendino-
sus muscle. The injection was followed by constant
current EP (CELLECTRA® device, VGX Pharmaceuticals
Inc., The Woodlands, Texas) at 0.5 Amps, 3 pulses of 52
milliseconds each, 1 second between pulses with an IM
applicator consisting of 1.375 ± 0.020 inch long 21-gauge
needles in a pentagonal arrangement [50]. Animals were
allowed to recover from the anesthesia before rejoining
their owners. Control animals underwent the EP proce-
dure but were not injected with the GHRH-plasmid.
Body Weight, Blood and Urine values
Animals were weighed before the plasmid injection and at
three post-treatment time points post-injection/EP using
the same calibrated scale. One pre-injection/EP blood
draw (day 0), and three post-treatment draws (at approx-
imately days 20, 40, 75) were performed. Blood and urine
samples, obtained by standard veterinarian practice, were
analyzed for biochemistry, metabolism and hormones.
Complete blood count (CBC), biochemistry and hor-
mone values for day 0 served as baseline reference for each
dog or cat. Whole blood was collected in Monoject® Lav-
ender Stopper blood collection tubes with 3.0 mg EDTA
Circulating iron concentration in GHRH-treated dogs Figure 2
Circulating iron concentration in GHRH-treated 
dogs. The results are presented as means ± SEM. Circulating 
iron concentration is significantly improved in dogs treated 
with plasmid-mediated GHRH (where * P < 0.05).
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Protein metabolism in cats with chronic renal failure treated  with plasmid-mediated GHRH therapy Figure 3
Protein metabolism in cats with chronic renal failure 
treated with plasmid-mediated GHRH therapy. The 
results are presented as means ± SEM. Protein metabolism is 
significantly improved in cats treated with plasmid-mediated 
GHRH (where * P < 0.05) whereas control cats do not show 
any significant differences over the time points measured.BMC Biotechnology 2009, 9:4 http://www.biomedcentral.com/1472-6750/9/4
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(Sherwood Medical, St. Louis, MO) and submitted for
CBC analysis (Antech Diagnostics, Irvine, CA). Serum was
aliquoted for radioimmunoassay and biochemical analy-
sis (Antech Diagnostics, Irvine, CA).
Plasma IGF-I
IGF-I levels were not determined in control animals as
there were too few blood samples to warrant statistical
testing (as only a small number of animals survived to the
end of the study); IGF-I levels were measured in treated
dogs and cats throughout the study and compared to
baseline values. IGF-I levels were measured by heterolo-
gous human radioimmunometric assay from collected
blood samples (Diagnostic System Lab., Webster, TX). The
sensitivity of the assay was 0.8 ng/ml; intra-assay and
inter-assay variation was 3.4% and 4.5% respectively. All
samples were analyzed in the same assay and the intra-
assay variability was 4.2%.
Statistics
A Microsoft Excel statistics analysis package was used. Val-
ues shown in the Figures are the mean ± SEM. Specific P
values were obtained by comparison using ANOVA. P <
0.05 was set as the level of statistical significance.
Abbreviations
GHRH: growth hormone-releasing hormone; GH: growth
hormone; IGF-I: insulin-like growth factor-I; CRF: chronic
renal failure; EP: electroporation; QOL: quality of life;
PVC: hematocrit; Hb: hemoglobin; RBC: red blood cell;
MHC: mean red blood cell hemoglobin.
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BUN and Creatinine levels and ratio for GHRH-treated dogs and cats Figure 4
BUN and Creatinine levels and ratio for GHRH-treated dogs and cats. The results are presented as means ± SEM. 
The BUN (A) and creatinine (B) levels remained unchanged for the GHRH-treated dogs while control animals displayed an 
increase in BUN and creatinine at 75 days compared to day 0. (C) The BUN/creatinine ratio in cats was not significantly altered 
in the GHRH-treated animals but control cats showed an increase at day 75 compared to day 0.
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